PleoPharma, Inc.

About PleoPharma, Inc.

PleoPharma, Inc. is a pharmaceutical company focused on developing therapies to address unmet and growing needs in the central nervous system (CNS) and substance abuse space. Their mission is to meet the significant demand for treatments of medical conditions where no FDA-approved solutions currently exist, helping millions who suffer needlessly.

Products & Services

Lead Program:A therapy in development for CNS and substance abuse conditions, which has successfully completed Phase 2 and is receiving enthusiastic support.

Specialties

Central Nervous System (CNS) therapies Substance abuse treatments

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 36000000 MR: - FA: $36 Million FAN: 36000000	D: 2025-10-21 FD: 2025-10-21	3 investors

Series B Latest

2025-10-21

$36.0M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

G

Ginger Constantine

Chief Executive Officer, Co-Founder and Chairperson of the Board

T

Thomas Poché

General Counsel and Head of Intellectual Property

A

Adeyinka Abinusawa

Chief CMC Officer, Consultant

D

Dawn Halkuff

Head of Investor Relations

K

Kristine Craig

Senior Director of Quality Assurance

R

Robert Finizio

Executive Director

View 18 more team members with Pro

Unlock Full Team Directory

Recent News

PleoPharma, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised